GlassScriptPhysician profile
Fathima Chowdhury
NPI 1760823132
$75,893.39
in general payments reported to CMS, 2019-2025
31 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,630 · 2022: $1,643 · 2023: $2,996 · 2024: $46K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Travel and Lodging: $7,815 · Food and Beverage: $5,815 · Consulting Fee: $2,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,670.00 |
| Travel and Lodging | $7,815.29 |
| Food and Beverage | $5,815.29 |
| Consulting Fee | $2,320.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $69,415.67 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $950.49 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $799.44 | 2021-2025 | Caplyta |
| Abbvie INC. | $591.04 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $563.08 | 2021-2024 | Ingrezza |
| Corium, LLC | $398.64 | 2021-2023 | Azstarys |
| Alkermes, INC. | $371.40 | 2022-2024 | Lybalvi, Aristada, Vivitrol |
| Neos Therapeutics, LP | $350.76 | 2021-2023 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $327.45 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Lundbeck LLC | $274.60 | 2022-2025 | Rexulti |
| Indivior INC. | $271.59 | 2021-2025 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $195.60 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $195.27 | 2023 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $137.86 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.42 | 2021-2023 | Trintellix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $122.97 | 2022-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $107.03 | 2025 | Cobenfy |
| Almatica Pharma LLC | $100.36 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $90.55 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $81.72 | 2024 | Invega Sustenna, Invega Trinza |
| Tris Pharma INC | $60.82 | 2022-2023 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $57.59 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $53.88 | 2024 | Qelbree |
| Braeburn INC. | $46.12 | 2024 | Brixadi |
| Neuronetics, INC. | $38.64 | 2021 | |
| Noven Therapeutics, LLC | $37.29 | 2023 | Xelstrym, Secuado |
| Avion Pharmaceuticals | $32.58 | 2023 | Methylphenidate Hydrochloride |
| Orexo US, INC. | $25.07 | 2022-2023 | |
| Sage Therapeutics, LLC | $23.84 | 2023 | |
| Bausch Health US, LLC | $19.17 | 2021 | |
| Vanda Pharmaceuticals INC. | $15.45 | 2025 | Hetlioz, Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fathima Chowdhury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.